Skip to content


Just another site

Mostly a good effect.

The value of Niaspan for patients with type 2 diabetes has been assessed in a multicenter, double-blind study.[35] This study involved 148 patients with diabetes in conjunction with dyslipidemia or an abnormal lipid profile primarily characterized by low HDL levels and elevated triglyceride levels. Participants were randomly assigned to receive Niaspan 1000 or 1500 mg/day or placebo for 16 weeks.

The authors concluded that Niaspan has minimal effect on glycemic control in most patients with diabetes and that it effectively modifies dyslipidemia.


%d bloggers like this: